CN102099051A - 利用聚乙二醇化的iii型干扰素治疗丙型肝炎 - Google Patents

利用聚乙二醇化的iii型干扰素治疗丙型肝炎 Download PDF

Info

Publication number
CN102099051A
CN102099051A CN2009801261152A CN200980126115A CN102099051A CN 102099051 A CN102099051 A CN 102099051A CN 2009801261152 A CN2009801261152 A CN 2009801261152A CN 200980126115 A CN200980126115 A CN 200980126115A CN 102099051 A CN102099051 A CN 102099051A
Authority
CN
China
Prior art keywords
interferon
patient
pegylation
polypeptide
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801261152A
Other languages
English (en)
Chinese (zh)
Inventor
D·F·豪斯曼
M·G·多德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Bristol Myers Squibb Co
Original Assignee
Zymogenetics Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Bristol Myers Squibb Co filed Critical Zymogenetics Inc
Publication of CN102099051A publication Critical patent/CN102099051A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2009801261152A 2008-06-05 2009-06-05 利用聚乙二醇化的iii型干扰素治疗丙型肝炎 Pending CN102099051A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5923708P 2008-06-05 2008-06-05
US61/059,237 2008-06-05
US10945508P 2008-10-29 2008-10-29
US61/109,455 2008-10-29
US16776309P 2009-04-08 2009-04-08
US61/167,763 2009-04-08
PCT/US2009/046451 WO2009149377A1 (en) 2008-06-05 2009-06-05 Use of pegylated type iii interferons for the treatment of hepatitis c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310408018.0A Division CN103536906A (zh) 2008-06-05 2009-06-05 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎

Publications (1)

Publication Number Publication Date
CN102099051A true CN102099051A (zh) 2011-06-15

Family

ID=41020837

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801261152A Pending CN102099051A (zh) 2008-06-05 2009-06-05 利用聚乙二醇化的iii型干扰素治疗丙型肝炎
CN201310408018.0A Pending CN103536906A (zh) 2008-06-05 2009-06-05 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310408018.0A Pending CN103536906A (zh) 2008-06-05 2009-06-05 利用聚乙二醇化的iii 型干扰素治疗丙型肝炎

Country Status (8)

Country Link
US (1) US20110165121A1 (https=)
EP (1) EP2296691A1 (https=)
JP (1) JP2011522834A (https=)
CN (2) CN102099051A (https=)
AU (1) AU2009255994B2 (https=)
CA (1) CA2727026A1 (https=)
RU (1) RU2496514C2 (https=)
WO (1) WO2009149377A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533840A (zh) * 2011-12-13 2012-07-04 江南大学 毕赤酵母制备人白细胞介素29成熟肽的方法
CN103228792A (zh) * 2011-08-25 2013-07-31 纳诺亘医药生物科技公司 PEG-干扰素λ1结合物
CN111065405A (zh) * 2017-09-08 2020-04-24 科学未来管理有限责任公司 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法
CN115968291A (zh) * 2020-04-22 2023-04-14 南湖制药公司 聚乙二醇化干扰素tau及其组合物和方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927040B2 (en) 2000-06-30 2005-08-09 Zymogenetics, Inc. Interferon-like protein Zcyto21
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
EP1927600A1 (en) 2003-08-07 2008-06-04 Zymogenetics, Inc. Homogeneous preparations of IL-28 and IL-29
WO2005097165A2 (en) 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US20120308517A1 (en) 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
WO2012031763A1 (en) * 2010-09-08 2012-03-15 Twincore Zentrum Fuer Experimentelle Und Klinische Infektionsforschung Gmbh Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013029062A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Co., Ltd Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
CN104045704B (zh) * 2013-03-11 2016-08-10 中国医学科学院基础医学研究所 PEG化重组人IFN-λ1、其制备方法和用途
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US10246501B2 (en) * 2014-01-08 2019-04-02 Prosit Sole Biotechnology (Beijing) Co, Ltd Fusion polypeptides and methods of use
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
ES2751652T3 (es) * 2014-05-12 2020-04-01 Conatus Pharmaceuticals Inc Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
GB201621728D0 (en) * 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
JP2019107021A (ja) * 2019-03-05 2019-07-04 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
AU2020249331B2 (en) 2019-03-25 2026-02-05 F. Hoffmann-La Roche Ag Solid forms of a compound of HBV core protein allosteric modifier
US20220370447A1 (en) * 2019-09-20 2022-11-24 Hoffmann-La Roche Inc. Method of treating hbv infection using a core protein allosteric modulator
WO2021119749A1 (en) * 2019-12-20 2021-06-24 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097165A2 (en) * 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
WO2007012033A2 (en) * 2005-07-20 2007-01-25 Zymogenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
CN1910200A (zh) * 2003-08-07 2007-02-07 津莫吉尼蒂克斯公司 Il－28和il－29的均一化制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927040B2 (en) * 2000-06-30 2005-08-09 Zymogenetics, Inc. Interferon-like protein Zcyto21
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
EE05509B1 (et) * 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
EP1575609A4 (en) * 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
CA2574564C (en) * 2004-07-29 2013-04-16 Zymogenetics, Inc. Use of il-28 and il-29 to treat cancer and autoimmune disorders
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
CA2616004A1 (en) * 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
WO2007041713A1 (en) * 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1910200A (zh) * 2003-08-07 2007-02-07 津莫吉尼蒂克斯公司 Il－28和il－29的均一化制剂
WO2005097165A2 (en) * 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
WO2007012033A2 (en) * 2005-07-20 2007-01-25 Zymogenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228792A (zh) * 2011-08-25 2013-07-31 纳诺亘医药生物科技公司 PEG-干扰素λ1结合物
CN102533840A (zh) * 2011-12-13 2012-07-04 江南大学 毕赤酵母制备人白细胞介素29成熟肽的方法
CN111065405A (zh) * 2017-09-08 2020-04-24 科学未来管理有限责任公司 口服生物利用度高的聚乙二醇化干扰素λ及其制备方法
CN115968291A (zh) * 2020-04-22 2023-04-14 南湖制药公司 聚乙二醇化干扰素tau及其组合物和方法

Also Published As

Publication number Publication date
AU2009255994A1 (en) 2009-12-10
EP2296691A1 (en) 2011-03-23
WO2009149377A1 (en) 2009-12-10
US20110165121A1 (en) 2011-07-07
CA2727026A1 (en) 2009-12-10
CN103536906A (zh) 2014-01-29
JP2011522834A (ja) 2011-08-04
AU2009255994A2 (en) 2011-02-17
RU2496514C2 (ru) 2013-10-27
RU2010154092A (ru) 2012-07-20
AU2009255994B2 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
RU2496514C2 (ru) Применение пэгилированных интерферонов типа iii для лечения гепатита с
US8318147B2 (en) Use of IL-29 for treating a dengue virus infection
US8283448B2 (en) Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
US8597635B2 (en) Interferon alpha-2B modified by polyethylene glycol and methods of preparation thereof
US20120035347A1 (en) Interferon-alfa sensitivity biomarkers
US11534479B2 (en) Use of interleukin 2 for treating Sjögren's syndrome
US7456257B2 (en) Fusion proteins of interferon alpha muteins with improved properties
US8597634B2 (en) Interferon alpha-2a modified by polyethylene glycol and methods of preparation thereof
US20090214472A1 (en) Interferon-beta polymer conjugates
CN103228792A (zh) PEG-干扰素λ1结合物
CN102584979B (zh) PEG化干扰素λ
AU2004286835A1 (en) Use of interferon-tau in medicine
Overall et al. Functional analysis of interferon-α subtypes using monoclonal antibodies to interferon-α 4a—subtype reactivity, neutralisation of biological activities and epitope analysis
TWI913263B (zh) 對介白素-2受體βγc二聚體具偏性且結合至非肽、水溶性聚合物之人類介白素-2結合物
WO2013029062A1 (en) Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110615